Anebulo Pharmaceuticals Inc (ANEB)

Dec 23, 2024, 9:15 AM EST - 25 days ago

Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

Nov 13, 2024, 4:05 PM EST - 2 months ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

Sep 25, 2024, 4:05 PM EDT - 4 months ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

Jul 22, 2024, 7:00 AM EDT - 6 months ago

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

May 15, 2024, 1:15 PM EDT - 8 months ago

Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development

May 15, 2024, 1:05 PM EDT - 8 months ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

Feb 13, 2024, 4:05 PM EST - 1 year ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Nov 14, 2023, 4:05 PM EST - 1 year ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

Oct 6, 2023, 4:06 PM EDT - 1 year ago

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

Oct 6, 2023, 4:06 PM EDT - 1 year ago

Anebulo Pharmaceuticals Announces New CEO

Sep 20, 2023, 4:29 PM EDT - 1 year ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

May 11, 2023, 8:00 AM EDT - 1 year ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

Mar 28, 2023, 8:00 AM EDT - 1 year ago

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

Mar 8, 2023, 8:00 AM EST - 2 years ago

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

Feb 10, 2023, 8:38 AM EST - 2 years ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

Jan 27, 2023, 3:49 PM EST - 2 years ago

Anebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear

Jan 9, 2023, 8:00 AM EST - 2 years ago

Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

Nov 10, 2022, 8:00 AM EST - 2 years ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates

Nov 1, 2022, 4:00 PM EDT - 2 years ago

Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

Sep 26, 2022, 7:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing

Sep 26, 2022, 7:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Sep 20, 2022, 8:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022

Sep 9, 2022, 8:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress

Aug 23, 2022, 5:00 PM EDT - 2 years ago

Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26

Jul 5, 2022, 8:00 AM EDT - 2 years ago

Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants

Jul 5, 2022, 6:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Jun 23, 2022, 4:00 PM EDT - 2 years ago

Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

May 24, 2022, 4:00 PM EDT - 2 years ago

Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

May 11, 2022, 9:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

Apr 1, 2022, 7:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission

Feb 11, 2022, 9:13 AM EST - 3 years ago

Anebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid Intoxication

Feb 11, 2022, 8:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates

Jan 6, 2022, 7:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations

Jan 6, 2022, 7:00 AM EST - 3 years ago

Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Jan 4, 2022, 7:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

Jan 3, 2022, 7:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Nov 12, 2021, 8:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Oct 13, 2021, 8:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose

Oct 12, 2021, 8:59 AM EDT - 3 years ago

Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem

Sep 23, 2021, 10:49 AM EDT - 3 years ago

CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials

Sep 22, 2021, 4:05 PM EDT - 3 years ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update

Sep 13, 2021, 8:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial

Sep 7, 2021, 8:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Aug 12, 2021, 8:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members

Jun 22, 2021, 10:27 AM EDT - 3 years ago

Cannabinoid-Focused Anebulo Pharma Posts Q3 Earnings, On Schedule To Start Cannabis Overdose Clinical Trials

Jun 21, 2021, 4:05 PM EDT - 3 years ago

Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Results

May 8, 2021, 11:29 PM EDT - 4 years ago

U.S. IPO Weekly Recap: Sacramento Bank Five Star Bancorp Finishes On Top In An 8 IPO Week

FSBC BWMN HNST WDH

May 7, 2021, 12:36 PM EDT - 4 years ago

4 Companies Open for Trading

BWMN WDH

May 6, 2021, 8:00 PM EDT - 4 years ago

Anebulo Pharmaceuticals Announces Pricing of Initial Public Offering